Status:
RECRUITING
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
Lead Sponsor:
Benedito Mauro Rossi
Conditions:
Pancreatic Cancer
Metastasis
Eligibility:
All Genders
18+ years
Brief Summary
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whet...
Detailed Description
Pancreatic cancer, particularly Pancreatic Ductal Adenocarcinoma (PDAC), has an extremely poor prognosis, with a 5-year survival rate of less than 3% for advanced stages. In 2020, Brazil saw about 11,...
Eligibility Criteria
Inclusion
- Patients diagnosed with metastatic PDAC;
- Patients who will start treatment with FOLFIRINOX;
- 18 years or older;
- Who agree to participate in the study by signing the Informed Consent Form;
Exclusion
- Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
- Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Key Trial Info
Start Date :
January 21 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06945978
Start Date
January 21 2025
End Date
December 1 2027
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
A Beneficência Portuguesa de São Paulo
São Paulo, São Paulo, Brazil